Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Nightingale, Financial statements release for financial year 2024–2025

By Inderes9/18/2025, 11:00 AM
Nightingale Health

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Teemu Suna
00:02 - 41:12

Good afternoon and welcome to the Nightingale Health webcast for the full year results. So today, our agenda is that I will start by talking about our technology and products. Then we move on to the business targets of the past fiscal year. Then we will have a look at the key achievements. Then we have the financial review and then Tuukka Paavola. Our CFO will join me on stage for that part. Then we have business targets for the ongoing fiscal year. Then we have the financial calendar and the AGM. Then I will talk about some significant events that occurred after the end of the period. And then at the end, we have a Q&A. Our Chief Operating Officer, Ryan Aranda, will join us on stage for the Q&A. Please post your questions. My name is Dan. I'm the CEO and founder of Nightingale Health. So let's start. So why does Nightingale exist? We exist to build better healthcare for everyone. And now, when I say everyone, I mean everyone: I mean citizens. I mean healthcare professionals. I mean institutions, I mean taxpayers, I mean everyone. And this is all about solving healthcare's biggest challenge. So why do we need to solve healthcare challenges? Well, if we look at healthcare, in the big picture, the costs of healthcare are up to 18% of the gross domestic product. To provide some context, this is approximately four times more than military spending. And this applies, as the top-line percentage is different in different countries. But the ratio is pretty much the same. It's also not only about money. The way healthcare is organized today also causes suffering. So we live longer than ever. Yet, we are sicker than ever. So if we look at this in a bit more detail. 75% of all deaths globally are caused by preventable chronic diseases. Chronic diseases cost tens of trillions of dollars globally. And then if we look to the future, it's not getting better. So by 2030, it's estimated that the total cost will rise to 47 trillion dollars. So when I'm talking about it, healthcare has a big problem. The problem is massive. So why do we have this problem? The current healthcare logic has two key elements that are very challenging. Healthcare is not healthcare. It's actually sick care. The healthcare system today is specialized in treating the sick, which is of course very important, but it's not focused on preventing disease progression. It's kind of a system that waits for people to get sick and then tries to solve the problem. Then another major challenge is that in healthcare, there is a huge conflict of interest. This conflict of interest is that the more there is sickness, the more there is money. And this applies to the public sector. So the public sector will need to allocate more money. The more there are sick people. This also applies, of course, in the private sector. So the more there are sick people, the more there is business. So the current healthcare logic is broken. So how do we fix it? The only way that I think is very well acknowledged. The only way to fix it is by preventing diseases at scale. Because the problem is so huge, the only way to change the game is to have fewer sick people. How can you have fewer sick people? You need to be able to prevent disease progression and do it at scale. So let's simplify what this means, what prevention means. So here we have a very simple graph describing that as people get older. There are more sick people in the population. When we prevent diseases, when we have a systemic prevention for diseases, we can significantly reduce the prevalence and impact of chronic illnesses. We move the line. Because of that, we have fewer sick people. When we have fewer sick people, we have lower costs and less suffering. So I feel many times when talking about healthcare around the world, the issues often seem extremely complicated. I think it's not complicated, but it's about focusing on the right thing. This is what we need to solve. We need to change the logic in healthcare to be more preventative, to have fewer sick people. This is a real solution. This is actually changing. The key challenges in healthcare. So, let's have a look as I mentioned that the logic of healthcare is broken. So, let's have a look at how the logic actually should work. And now the important point is that this will not be solved by an amazing lifestyle improvement app, even though that is also needed. But this problem is not solved with an app. It's a kind of single-point solution. This will not be solved by advancements in genomics or any other next-generation omics technology. We need them. This is a systemic problem. It needs a systemic solution. And this is something that is often not properly understood. So you need to be able to build a complete feedback loop that encourages the system or incentivizes the healthcare system to reduce the risks at the population level. So it all starts by introducing a good, scalable, reliable, and repeatable way to beautifully detect risks in the population. So this is not healthcare that is targeted at the sick. This is healthcare that is targeted for everyone. Because in order to do prevention, you need to identify those in the population who are at high risk, and they are mostly healthy. So you need a risk detection technology that scales to the entire population without burdening the healthcare system. This is an extremely difficult specification for the technology. But once you have that, you can detect the risks at the population level in a repeatable and objective way. I will come back to this objective way later in the presentation. Then once you find the ones who are at risk, you perform preventative actions in a targeted manner for those who actually need them. Here, the key thing is that it's not enough just to detect the risk. You need to be able to also. Communicate the risk to people who are at high risk, to motivate them to change their behaviors or adhere to their medications. So you need a tool that can effectively motivate individuals at high risk to make the change. So, you first need detection on a population scale. Then you need a tool to motivate people to take preventive actions. And then once you have applied the interventions. You need to be able to track how well these interventions have worked. How do you do this? Well, you need to have a technology that can detect the risk. Again, in a repeatable and objective manner. So first, you detect a risk. Then you apply the interventions to the people at high risk. And then you measure again. And then you track the change in the risk level. If the risk goes down, it means that the applied intervention had good efficacy. Now, in order to do this, the risk detection method needs to be very repeatable and very objective. And just to give an example, the current tools in healthcare cannot do this because they are often based on questionnaires or subjective clinical measurements such as blood pressure. It depends on who takes the blood pressure. It depends on the situation when it's taken. It depends if the person is nervous in the situation or not nervous. Good thing to measure. It is a good thing to measure, but to build a preventative healthcare system, it does not work very well because it's not repeatable. So you need something that can actually repeat the risk assessment in an objective way. Again, to understand the efficacy of the preventative actions. When you have these three things, then this starts to work. But you need all three. And then, what do you do when you have this? You build a funding mechanism that actually allocates money for risk-reducing interventions. This is how we change. This is how we can change healthcare to get better results. This is how we can reduce the costs. This is how we can reduce suffering. However, it needs to be built at a systemic level to be effective, and it should serve as a complete end-to-end solution. So I mentioned that the current tools in healthcare have limitations. Let's talk in a bit more detail about risk detection. So the risk detection is already being done. Every healthcare system does this. So they try to figure out the risk for people and then take some actions based on the risk. The current clinical standard involves using clinical risk calculation calculators. So we have the Framingham score. We have a score, a score 2. We have Q risk. We have different methods for cardiovascular disease. We have a FINDRISC for type two diabetes. So we have these calculators. They perform risk detection quite well, but the process is very manual. They require a lot of questionnaires. They need clinical measurements such as blood pressure, BMI, etc. They need healthcare professionals' time. Because of the subjectivity of the data, I said that risk detection is good, but there is a clear compromise due to the data's subjectivity. Then we have everybody talking about AI. So I think I also need to talk about AI. We have different AI risk models. The benefit of AI is that it can be very, very automated, but the reliability. Now, I encourage everyone to think back to the feedback loop that I described. If you implement an AI model and try to track the difference in risk before and after the intervention, the data consistency in healthcare is just not good enough. And the AI model is only as good as the data that is used for the input. So this is not a feasible solution to do it on a systemic level. However, they are good tools. They are tools. So this is what we do very well. This is where we are the best in the world. So we can perform risk detection with high reliability, high repeatability, and in a highly automated fashion. We don't use this subjective data. We have no questionnaires. We have no subjective, clean clinical measurements. We use molecular medicine to detect the risks for multiple chronic diseases simultaneously because we only use blood. We don't need healthcare professionals' time. I mean, risk detection. You just get one blood sample and that's it. And because of this, it can be super automated, and because of this, it has very high repeatability. And because of this, the Nightingale technology can actually be the foundation of a preventative healthcare system. So I want to talk a bit about how we do this and take it to a more detailed level. So as I said, only a single blood sample is needed. Why is this important? I mean, there are many exciting things from the technological point of view. Like, how can we do it? And I think it's also very exciting. But the real reason why this is interesting is that this enables us not to use healthcare professionals. Time for risk detection is minimized because blood samples can be collected efficiently. You can obtain blood samples with very high throughput and at a significantly low cost. So I think that's the exciting part. So it means that you can take it to a national level. You can offer this technology to everyone. And it's not only that the technology allows it. We also have a price point that makes it feasible. You can run this for everyone, and when you do it for everyone, you are actually moving the healthcare system towards preventive healthcare. So what do you get when you run this thing? When we run this single blood sample. So you get here, we have our clinical report. So our clinical report performs routine risk assessment for common chronic diseases. And I will work through the different parts of the report, and we will zoom in a bit to the specific parts of the report to explain how this technology actually enables the full feedback loop in preventative healthcare. So let's start with the risk detection. So again, one blood sample with Nightingale's technology. And we provide routine risk detection for multiple diseases. We have heart attack, stroke, type 2 diabetes, chronic kidney disease, and fatty liver disease. Every time from every sample. And we provide the information about the risk in a very visual and easy-to-understand way. This is the clinical summary. And now think about this from the clinical use point of view. So if you were a clinician using the traditional method to evaluate risk for heart attack, stroke, type two diabetes, chronic kidney disease, and fatty liver disease, it takes a significant amount of your time. You need to do questionnaires. You need to perform clinical measurements. You need to do blood testing. So, you need a lot of work. We are talking about this. This process easily requires a significant amount of time to complete all of that. You spend an hour or even more to get it done. And then you have to manually use different calculators to input the data and evaluate everything separately. It's not feasible. Nobody does it. Would it be important to do? Oh, yes. This is the way if we want to bring a preventive healthcare system. You definitely want to do this. I think everyone agrees that detecting the risks is important. Now, with Nightingale, it takes 30 seconds for a clinician to see the risk situation of a patient. I think it's quite cool. And then what you can do in addition to supporting the clinician is use this to steer the whole healthcare system. So, for example, if you have people who have all red balloons, indicating every disease is at high risk, you can automatically steer that person to a treatment workflow that is specialized for that situation. You can automatically categorize the risks, depending on whether there is a person at risk for type two diabetes. You can also refer the person to a specialist who is focused on that disease. So you can perform disease-specific automatic steering of people. Guide them to the right experts. Automation is the key word here because when building a preventative healthcare system, it has to be automated. However, with this, you can automate the process. And again, you can do it because the data is objective. It doesn't have any subjectivity bias. Blood doesn't know, the molecules in the blood don't know that they cannot answer incorrectly to a questionnaire. It's just the molecules. So it's objective, okay. So we detect the risk. And then we provide a more detailed page for each of these diseases that describes the risk. And now, this page is the tool for the clinician and the patient to ensure that the clinician can communicate the risk situation to the patient very clearly. So this is the motivation part. I will walk you through and pretend to be a clinician to explain the report. So, dear patient, your current risk for a heart attack in this case is 18%. So I know that 18% may not be very easy to understand, but if you look at the number below 18%, you see a number 6%, which is the average risk for men at 60. So the patient here is also male, 60 years old. Now you see that the average risk is 6%, and you have 18%. So it means that your risk is very high because it is actually three times higher than the average. And now it's very important that we take actions to reduce your risk. Because if we don't do anything, in 15 years, if you read the graph towards the right corner, you see that at 75 years old, your risk is 49%. Every other person will have a heart attack. And then below the 49%, you see the average risk, which is 17%. One big problem in this risk detection is how to communicate the risk in an understandable way. This is the clinical way of showing the risk, which is using percentages. Et cetera. However, with this approach, it's much easier to understand the risk situation than with any of the calculators currently used. You can go and have a look at the calculators. There are many of them publicly available. So this communicates the risk situation in a way that it's easier to understand for the patient. And with this, it motivates either to adhere to the medication, to make lifestyle changes, or to do both. Okay, now we do the prevention. We have a tool to do the prevention. We help clinicians to do it efficiently, quickly explaining the situation to the patient. Now, if you follow, if you think about the feedback loop I was talking about, the first page in the report was detection. Now we talk about prevention. And the next part is, of course, to measure the change. So after the clinician prescribes the intervention for the individual, the doctor says to come back in three months. Come back in six months. We take another blood sample. We measure the risks again, and we show how the risk has changed. And now there are many use cases for this; one is that there is a globally significant problem with medication adherence, with people not taking their prescribed medications. One reason is that when you take the medication, you don't feel any immediate effects. With this, we can show how the actual risk situation changes, and everything reflects back on all of the reports. So it's a tool to track the efficacy of the interventions. It's very important, of course, for the patient and the clinician. But let's take a bit of a bigger picture. This is important for the healthcare service provider. Today, healthcare does not have a clear understanding of the performance of the healthcare system. Why? Because there are no tools available that allow you to consistently repeat the measurement and track progress. And again, we can do it because we have objective data. We can repeat the measurement in a reliable way. So then the healthcare provider can compare different intervention pathways and figure out which of those are actually working well. For example, someone might say that they have an amazing lifestyle improvement app. The diseases we are examining. They are all lifestyle diseases. 80% of the risk is determined by lifestyle in these diseases. So how does the healthcare provider know if the app is actually working? Well, the traditional way to do this is to send questionnaires to the app users and ask how happy they are. So you use a lot of subjective data to evaluate the performance, which I think is fine to do, but this is a different level. What I'm talking about here. It examines the molecular level. If the risk to develop the outcomes. So the disease has actually changed. And now let's take a step back to look at the bigger picture. Let's consider a nation. So now if you aggregate the data from these individual follow-up measurements, you can actually start tracking the entire healthcare system. So if a country makes a change in health policy and introduces a sugar tax. So you make sugar-based products more expensive for people to buy. How do you know if that health policy change is working? You wait 15 years for results with this. If you run this as a part of your routine healthcare risk assessment, you see the indication in a year or two. Because you consistently repeat the testing, you can connect the change in risk back to the actions taken by the government, the healthcare provider, or the individual clinician. This is the ability to track the performance of healthcare. This is a novel concept. I'm not aware of any other tool that can do it in such a reliable way. So, to build a preventive healthcare system, we need a systemic solution for it. We need to be able to detect the risks at scale. We need to be able to prevent diseases in a targeted manner. We need to be able to measure the change in risk, and then we can connect the funding mechanisms to encourage risk-lowering actions. This is what Nightingale does. This is why we exist. I believe this technology will change how healthcare is conducted worldwide. Because this just makes more sense. And everything starts from a single blood sample. This is what I mean when I say we are building better healthcare for everyone. Alright, so we will move to the next segment and talk about the business targets of the past fiscal year. We had three targets: to win large international deals, to increase revenue, and to improve efficiency. The idea here with these targets is to have a clear commercial focus. So, increasing the commercial focus all the time while managing the investment ensures that we don't over-invest, given the situation with building what I just shared with you. It takes time. It can be done. But it's not something that you can just implement right away. It's not that kind of thing. You go to a store and buy a new iPhone. It's a bit more complicated to change how the system works. That's why we are putting a lot of effort into also managing the efficiency to have the flexibility with the runway. Where did we land? So, regarding the first target: We have very successfully built the funnel with exciting new projects in healthcare. So, a lot of negotiations are ongoing. A very big win for the past fiscal year was the agreement signed with the public sector in Finland. And this is exactly what I described just earlier, what we want to do in Finland. I think we are now taking the first and very strong steps in that area. In national public healthcare. Scope. We managed to increase the revenue by 7.7%. This is our revenue increase. I think it was a rather good achievement. Given how many things we are still building and ramping up, the uncertainty in the US market had a significant effect on our revenue last financial year and efficiency. The EBITDA decreased by around 15%. We need to invest to move things forward. It's very important to acknowledge that Nightingale Health Plc is a truly global company. So we run our operations in Japan, Singapore, the UK, Finland, and the US. So it's quite a lot to manage. And I think the team is working with these different global locations with extremely good efficiency. But of course, it requires some investments. I want to highlight a couple of things that took place in the past fiscal year. Here we have the global locations. I will be giving detailed descriptions from Finland, Singapore, and the US. In Finland, we achieved a significant milestone by collaborating with public healthcare. For the first time, I think this achievement is very significant. This has been a very long-term ambition for Nightingale. And it takes approximately ten years to get something together. New technology in primary care, in public healthcare. It's extremely complicated. It requires a massive amount of validation and evidence to get there. So because of that, this is a huge milestone for us. And I strongly believe that this is the direction that every healthcare system in the world is going to. What other options are there other than going forward? Preventive healthcare. What are their options? Just keep on increasing the costs. The costs. I think it's not possible. It's not only costs but also suffering that need to be considered. I think it's very clear that something needs to be done. Needs to be done. And this initiative in Finland, I think it's globally leading. Leading the way. In Singapore, we have also made very strong progress. I think it's a very strong indication of our global mission that we can complete the very strict regulatory requirements. Singapore has a very strict and demanding baseline for healthcare. And we have passed all of the required steps there. And now we are building up the commercial part of the business. But it needs to be done in an iterative way. So again, this is not something where you have one product and then you immediately go all over the world and say, okay, start implementing this. Healthcare does not work like that. So you have to establish the regulations. You have to build up the capability to deliver the product. Then you need to start building it with your colleagues, your first customers, ensuring that the product you are offering has, for example, the right tone of voice for clinicians. And it needs an iterative process to adapt to that. And then you can scale it out. But in Singapore, we are now getting very close to the moment when the commercial scale up will also take place in the United States. We have opened a new laboratory in Long Island City, New York. And now it's open for medical research customers. But there have been some uncertainties in the US market about the funding with the research institutions that have had an impact due to us. But I think the most important thing is that we are building the local capability there. It's, uh, there are several complexities involved. Complexities around it that are kind of outside of Nightingale. But I think we are making very good progress in navigating the environment. And because we have a strong customer base with very reputable names in the US already. I'm expecting that this fiscal year we can make very strong progress. Also in the US. Step by step, we are also making significant progress towards a much stronger position in the U.S. In the spring, we moved from the First North list to the main list on Nasdaq Helsinki. At the same time, we also implemented an ADR mechanism and made this stock available in the OTC market in the US. This is part of the strategy, as we are a global company. And we also need to take different steps to connect with the international capital markets better, so that with the OTC, that was the first step in that journey. And of course, that is connected to our project in setting up the new laboratory in the US. So these things go hand in hand. All right. So that was the review of the milestones in the previous fiscal year. Now it's time to look at the numbers. So welcome on stage. Tucker will talk to you about the numbers of the past fiscal year.

Tuukka Paavola
41:13 - 47:32

Thank you, Teemu. It's great to be here again. And good afternoon, everybody watching the stream. So let's, without further ado, jump into the exciting world of numbers. Let's start from the funding side of things. So, our liquid funds, i.e. Cash and current investments were at €51 million. At the end of June, at the end of the financial year, the change in liquid funds was roughly €15 million, which is actually about the same as in the previous financial year, which I think underlines the financial prudence with which we have been executing our global growth strategy. Now that we have the laboratory set up, basically up and running, we mentioned five laboratories in five countries, capturing all the key geographies in the world. We can actually now focus on increasing our revenue and concentrating on the sales side of things without much pressure to increase our operational expenses, which then means that all the sales growth we achieve, much of that will flow to the bottom line, i.e. improve our profitability. So entering this ongoing financial year, we have a really strong financial position with the 51 million of liquid funds giving us multiple years of runway to actually do what they just fantastically described to change the healthcare system in the world for the better. Focusing on the revenue side of things. The full year revenue was up by 8% year over year. And the second half revenue was actually quite nicely in line with the first half. So rather stable in the two halves. The good thing is that the healthcare revenue side of things is growing more and more rapidly. We currently receive it from Finland, Japan, and Singapore. And that is more stable in nature, balancing the more volatile research business, as we know. During the last fiscal year. So in the US, there are things happening in the environment that we can't actually influence. If we look at our sales pipeline, it's really strong. Also, the current cases we just announced after the financial year ended are contributing to this strong sales pipeline. So we expect that we will be able to reach the financial year target of at least 50% growth in revenue. Wrapping up the financial year. So the revenue landed at roughly 4.7 million, which represented a plus 8% year-over-year growth. The profitability was slightly lower, mostly due to the investments in the international expansion, but also there were some one-off expenses, such as the costs from the main transfer to Nasdaq Helsinki. We continued to prioritize financial efficiency, so the changes in liquid funds and net cash were in line with the previous financial year. And we have a really solid, strong financial position with multiple years of runway remaining. And basically, we don't have any debt. So that's also a possibility for a potential lever in the future if needed. Then the business targets for this ongoing financial year are short and sweet. We have one target: increase our revenue by at least 50% compared to the previous financial year, which means that we will be truly focusing on sales, continuing our growth, and continuing our commercial efforts. So that's where we will be focusing heavily this financial year. Then the mid-term and long-term targets actually remain the same. Furthermore, continue our global growth, become profitable in terms of EBITDA first, and then of course, down the line, also net profit-wise, to actually reach our long-term targets of generating €500 million in revenue. Finally, a few words about the financial calendar. So we will publish our annual report from the financial year that ended on the 30th of June 2025. During week 40. So in a few weeks, there will be an AGM on the 6th of November. And then the half year report will be published on the 5th of March 2026. Unlike usual, all the reports are available from our company's website. So those were the truly amazing numbers. And then a few words from them regarding some great news that have just recently happened.

Teemu Suna
47:33 - 52:14

Thank you, so we announced that we've been selected as the multiomics provider for a 2.4 million research project. I wanted to provide a bit more detail on this and answer the questions of why. Why Nightingale? So the competitive advantage that we have in the research market when it comes to multiomics offerings is that our technology, when we measure the sample and provide the Nightingale data, is non-destructive to the sample. So we measured the sample. It comes out of the machine. Kind of undestroyed. You can still use the same sample to run some other assays. For example, in this case, proteomics. Now, this may not sound so special to those who are not familiar with medical research. But if we put it this way, when research projects start to recruit volunteers to provide their blood samples and store them in a freezer for ten years, 20 years, etc., the amount of blood in the freezer is usually very little. But everybody understands that you cannot just take unlimited amounts of blood from a volunteer. If you have a volunteer for your project and you say, well, I want to take a bucket of blood, you don't get a lot of volunteers for that kind of approach. So you usually try to take as little blood as possible to get a lot of people into your cohort. So this makes the blood in the freezer extremely valuable. Calculate the cost of obtaining the sample. Calculate the cost over ten years to collect all the follow-up data and everything. It's massively expensive, and now most of the technologies and methods used to analyze the samples. They actually destroy the sample when they analyze it. You cannot use it for anything else. Our technology does not destroy the sample. It provides very interesting data because this data is also valuable in research. It's kind of a link to the healthcare use. So you have a framework that you can use to translate the findings to healthcare use. Because Nightingale's technology is the only omics technology in the world that is already implemented in large-scale primary care applications. So, you get that data and then you also get proteomics data, in this case from the same sample. And because we are the only ones who can offer this kind of package. We believe that we have a very strong market position. Why is this happening now? Some of the new omics technologies, such as proteomics, are now increasingly advancing. So this is a very recent development. This is kind of state-of-the-art in medical research. And we have a very strong position to support and help scientific projects around the world to obtain robust data sets from a single sample, preserving as much sample material as possible. And because we provide it from one company, we can also be rather competitive regarding the price point. So it's a big opening around multiple omics, and we believe we are in a strong position when moving forward in this segment as well. All right. Now, let's move to the last part. So we have a Q&A. So you're welcome on stage. Let's have a look at what kind of questions we have today.

Tuukka Paavola
52:14 - 52:44

Yes, good afternoon to our online viewers, and good afternoon. It's good to be back here. You've talked for quite a while. So let's jump right into the questions. But thank you. It was very exciting to hear about the previous fiscal year. And also a very exciting start for this fiscal year. So let's start with a question, Tim. Could you summarize last fiscal year, what were the main accomplishments and what could have gone better?

Teemu Suna
52:44 - 53:53

Yeah. So I think last fiscal year, we put a lot more commercial focus on everything we do. But when looking at ramping up a new lab in New York, we worked a lot with regulations in Singapore. So there have been a lot of commercial activities with a very strong development angle. We also built up a new way of communicating the results. So we need to do a lot of development. But I think the very nice thing is that with this commercial focus, everything is now connected very clearly to commercial projects. Whereas earlier, it was more focused on the need to conduct R&D. It's just that you need to do R&D. So, I think it was a very strong transformation towards commercial operations, and it has created a very solid foundation for these fiscal years to put more and more effort into ramping up the commercial side of things.

Tuukka Paavola
53:54 - 54:00

Okay. What could have gone better? Do you have any comments on that? What will you improve this fiscal year?

Teemu Suna
54:00 - 55:02

Yeah. So what we will improve is that we have done a lot of work as a company with a strong focus on science, R&D, and development, where the iteration cycle in these areas is longer than in more commercial projects. We are in this transformation to have shorter iterations and increased speed. Of course, I always think that more speed would be good. So that's something we. We could have done even better. But then on the other hand, I'm thinking that now, having managed to do it over the past months and gaining a lot more speed, maybe it was a necessary learning process. But now, thinking back, maybe that could have gone better.

Tuukka Paavola
55:02 - 55:14

Okay. Thank you. So then, a question about revenue for you. Revenue stayed on the same track with a small improvement, but profitability was lower. Can you explain what caused this?

Teemu Suna
55:15 - 56:41

Yeah, sure. Of course, when you talk about profitability, there are two sides. On the one hand, you have the revenue and, on the other side, the costs, which then translate into profitability. I think on the cost side, we executed our plan. You know, we set up the laboratories. Of course, there are some costs involved. We are increasing our footprint, which is also increasing our operational expenses. But all of that was basically in line with the plan. So no surprises there. Then on the revenue side, I think again, there are two factors affecting that. One is the long sales cycles that we have spoken about earlier, which are also on the research side but are particularly significant on the clinical side. So it takes a long time to go from the start of negotiations to initiating a pilot and eventually generating revenue. And again, since the fiscal year ends on a certain date, that's essentially a hard stop. And then, like now, was it one week after our end of the fiscal year, we secured more or less a deal. Had that occurred a month earlier, it would have significantly altered our results. Timing is always, you know, unexpected. And then the other thing impacting the revenue is what has now happened in the US. So it is, you know, the biggest research market in the world. And then the new government, the new regime, basically shut down all the funding for the project. So that did have an impact on our revenue, unfortunately.

Tuukka Paavola
56:42 - 56:57

Okay, thank you. There are a lot of questions about our partnerships, especially in Singapore with Pathology Asia and in the US with Boston Heart Diagnostics. Could you give us a status update? Yes. What is happening there?

Teemu Suna
56:57 - 58:44

Yeah. So perhaps I should open up a bit about the staging of these types of projects. So first, you establish the partnership, then you build up the technical capability to actually deliver. Then you engage with colleagues and a small group of customers because you want to make sure that the product and the kind of small differences—I'm talking about very small differences—really, really matter. Clinicians, because they are usually in a hurry when they need to do their job, find it very important that the information is positioned and placed in a way that is easy for them to understand. And then once you have done that, you go to the broader market, because if you just shoot to the broader market immediately, you might ruin it if you have something small that is not appropriate. You cannot go back like, oh okay. We do it differently. So the learning process needs to be very, it's quite delicate how to do it now with Boston and particularly with Singapore. We are in a situation now where we have been working with a small group of customers, talking with many colleagues, and we are making very good progress in preparing to launch the launch version of the report with these small adjustments. So I believe this fiscal year will be when we start building the full commercial ramp-up.

Tuukka Paavola
58:44 - 58:58

Okay. Thank you. So let's come back to Finland and South Savo. Can you give a brief overview of the pilot project here in Finland with the South Savo Wellbeing Service County? And how important is that for Nightingale?

Teemu Suna
58:58 - 60:45

Yeah, well, it's a huge win. And I remember when starting this company, that was one of the things that I said to the first investors when talking about Nightingale, explaining what we want to do, saying, okay, we want to bring this technology to public healthcare. Now, ten years later, it's there. And I think we have managed to achieve many things in an extremely rapid way because many people may wonder, well, how can it take such a long time, but once started, it's quite challenging. It's quite difficult. But now that we are there, I'm talking about the feedback loop for preventive healthcare. There are many elements in that approach that we will actually build into that project. I'm also having many conversations with various governments, typically involving the Treasury and the Ministry of Health, because it's such a significant issue. Something needs to be done. And I think for Nightingale Solutions, we are receiving very strong feedback that it's similar to building a house. So this is the foundation for your prevention. And then when you have the risk baseline well understood, you can add other things. So this is like complementary. You can add your apps. You can add your other kinds of tools to the system. But we just have to build the foundation first. Otherwise, the house will collapse.

Tuukka Paavola
60:45 - 61:12

That's true. So, gentlemen, we're running out of time. But would you still like to ask a few questions? Oh, yes. Yes. We are still asking a few questions. So multiomics, as you just announced some very exciting news. How has this expansion in your service offering been received by the market? And will there be other cases like the Arbery case coming in the near term?

Teemu Suna
61:12 - 62:07

Yeah, yeah. So I think it's been very well received. And I think the market very much appreciated the ability to preserve sample material. And then because it's like one. We are like one shop that does it all. It has certain cost advantages as well that we can provide for the benefit of the customer, which makes us very competitive in these different situations. So now, this is something that, of course, we've been discussing with many customers for a long time. The sales cycle is long, but now I think this is definitely a new offering that we will bring to our research portfolio. And, at least for now, it looks very, very positive. And our position is strong.

Tuukka Paavola
62:08 - 62:31

That sounds good. This is a question for both of you. So how does the near-term growth in terms of revenue look, and how does the sales funnel look, and how has it developed during the past fiscal year?

Teemu Suna
62:32 - 62:33

Look, I can start.

Tuukka Paavola
62:33 - 63:44

Yeah. So perhaps I'm reiterating myself. So I think the sales funnel looks really positive. And it looks positive in many different ways. It's strong in both research. And the clinical side is strong in many geographies. It's strong with different kinds of organizations. A lot of interesting discussions are ongoing. And we are confident that the target we set of at least 50% growth in revenue is achievable. Definitely. It's full focus on revenue, full focus on sales. But also, of course, as a CFO, I want to emphasize that we don't focus solely on sales. Of course, the cost side is also truly important. So we will maintain a level of financial prudence. We will only make extra investments where they are necessarily needed. By that, we hope that the increased revenue will start improving our profitability, and we will be on a good pathway towards our mid-term target of becoming EBITDA positive.

Teemu Suna
63:44 - 63:52

Right. And then if you could comment on that, where will this revenue come from? Is it mainly research or also from the healthcare side?

Tuukka Paavola
63:52 - 65:48

Yeah. So I think the research will still continue driving the revenue. This is partly because, with these especially big healthcare projects, there is a considerable amount of time it takes to build them up, get them into production, and scale them up. It just takes a long, long time. So, the balance is still there. But as Tuukka also said, the healthcare segment is building up all the time. It's also getting stronger on that side. And I think, like if you consider the competitive advantages of Nightingale now, this end-to-end loop in preventative healthcare, we know it's difficult to achieve. But when we get there, we believe we will have a significant advantage in the market. I think no one else, no one else can match our capabilities. We are not aware that there's anyone else who can actually do it. And then it opens up for us a very strong market. And in the meanwhile, also with the other offerings, we can take a much stronger position in medical research than we have had before because of the advantages of the technology. So I think on all fronts, we are making very strong progress. The question about the pipeline, if I compare it to 12 months ago, it's fundamentally different and fundamentally better. I believe all these activities are providing a very solid outlook at the moment. And we are very confident of the target we have. We have set and continue building the commercial traction for this fiscal year.

Teemu Suna
65:48 - 66:01

Okay, I think this is a great point to end this conversation. Thank you for participating in this Q&A. Do you have any final words for the viewers online before we end this meeting?

Tuukka Paavola
66:02 - 66:17

Well, no, I think we covered everything here pretty nicely. So it's time to say thank you. Have a nice day.

Teemu Suna
66:17 - 66:18

Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…